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1. 
METHOD FOR IDENTIFICATION OF 
VIRULENCE DETERMINANTS 
CROSS-REFERENCE TO RELATED 
APPLICATIONS 
This application is a divisional of U.S. patent application 
Ser. No. 09/759,287, filed Jan. 11, 2001, which claims the 
benefit of provisional application 60/175,433 filed Jan. 11, 
2000, the disclosures of which are hereby incorporated by 
reference in their entirety for all purposes. 
STATEMENT REGARDING FEDERALLY 
SPONSORED RESEARCH ORDEVELOPMENT 
This invention was made with government funds under 
98-35204-6761 and 99-35204-7789 awarded by United 
States Department of Agriculture/CSREES. The U.S. Gov 
ernment has rights in this invention. 
BACKGROUND OF THE INVENTION 
Paratuberculosis (Johne's disease) is an incurable, fatal 
disease of domestic and wild ruminants. Mycobacterium 
paratuberculosis (M. paratuberculosis) is the etiologic agent 
of this disease. Mycobacterium avium (M. avium) and M. 
paratuberculosis are slow-growing faculative intracellular 
mycobacteria able to grow in mononuclear phagocytes. 
DNA-DNA hybridization studies have shown that these 
micro-organisms belong to a single genomic species (Hurley 
et al., Intl. J. Syst. Bacteriol., 38: 143-146, 1988), and it has 
been proposed to reclassify M. paratuberculosis as a subspe 
cies of M. avium (Thorel et al., Intl. J. Syst. Bacteriol. 40:254 
260, 1990). Furthermore, all M. paratuberculosis strains are 
characterized by the presence of the insertion sequence IS900 
(Green et al., Nucleic Acids Res., 17:9063-9073, 1989), 
which is absent from most M. avium strains. Phenotypic 
differences between M. avium and M. paratuberculosis. Such 
as mycobactin requirement, ability to grow on egg medium, 
growth stimulation by pyruvate, and tolerance to cycloserine 
correlate with variations in pathogenicity and host range 
(Thorel et al., Intl. J. Syst. Bacteriol. 40:254-260, 1990). 
Johne's disease is manifested by chronic diarrhea and 
weight loss. After months of diarrhea and wasting, the 
affected animals either die or are culled. In the United States, 
the prevalence of M. paratuberculosis infection in dairy and 
beef cattle herds has reached 34% in certain areas (Collins et 
al., J. Am. Vet. Med. Assn. 187:323-329, 1992; Collins et al., 
J. Am. Vet. Med. Assn. 204:636-641, 1994) and results in 
millions of dollars in lost revenues annually. Furthermore, M. 
paratuberculosis has been tentatively linked to Crohn's dis 
ease, a chronic granulomatous ileitis in humans. Evidence 
Supporting the possibility that M. paratuberculosis is the 
etiologic agent of Crohn's disease includes culture of M. 
paratuberculosis is from intestinal tissue, and amplification 
by PCR of the subspecies-specific IS900 sequence of M. 
paratuberculosis from biopsy specimens. 
Natural infection in cattle is usually acquired in the first 
months of life. The age of onset of clinical Johne's disease 
varies, being most frequent during or after the second lacta 
tion in dairy cattle. The prolonged incubation time and the 
difficulty in diagnosing Subclinical cases facilitate the insidi 
ous spread of the infection within a herd. Bacteriologic cul 
ture is the most definitive diagnostic method, but requires 
substantial time and labor (Stabel, J. Vet. Diag. Invest., 9:375 
380, 1997), and it is unable to detect infected animals that do 
not shed acid-fast bacilli. Progress has been made by com 
10 
15 
25 
30 
35 
40 
45 
50 
55 
60 
65 
2 
bining fecal culture, PCR detection (IS900), and tests for 
humoral (ELISA) or cellular immunity (IFN-Y test) (Collins, 
Proceedings of the Fifth Intl. Colloq. Paratuberculosis, Chio 
dini et al., eds. Intl. Assn. for Paratuberculosis, 1997, pp. 
232-241.). More recently, a gene unique to M. paratubercu 
losis (hspX) was identified and has promise as a new diag 
nostic tool (Ellingson et al., Mol. Cell Probes 12:133-142, 
1998). 
Currently, treatment of paratuberculosis in cattle is limited 
to the extra label use of therapeutic agents (St.-Jean et al., Vet. 
Clin. N. Am. Food Anim. Pract. 7:793-804, 1991; St.-Jean, 
Vet. Clin. N. Am. Food Anim. Pract., 12:417-430, 1996), and 
no antibiotic treatment is recommended for clinical cases of 
Crohn's disease. Even with a prolonged drug regimen paratu 
berculosis in cattle is invariably fatal. 
Little is known about M. paratuberculosis immunogens 
and virulence determinants (Cocito et al., Clin. Microbiol. 
Rev. 7:328-345, 1994). Lipoarabinoman (Sugden et al., J. 
Clin. Microbiol., 29:1659-1664, 1991), glycopeptidolipid 1 
(Camphausen et al., Proc. Natl. Acad. Sci. USA, 82:3068 
3072, 1985), and 35 kDa (p35) antigen (El Zaatari et al., J. 
Clin. Microbiol., 35:1794-1799, 1997) are three major immu 
nogens. Antigen p35 was recognized by Sera from all clini 
cally diseased cattle and by fifteen out of twenty cattle with 
Subclinical diseases. This antigen, however, is not specific for 
paratuberculosis, since it is widely present in other strains of 
the M. avium complex. Several protein antigens have been 
identified by two-dimensional immunoelectrophoresis with 
hyperimmune Sera, but only a Subset of these antigens are 
recognized by Sera from animals with paratuberculosis (Gun 
narsson and Fedstand, Acta Vet. Scand. 20:200-215, 1979). 
Comparison of the two-dimensional gel electrophoretic pro 
files of M. paratuberculosis and M. avium cells grown in 
Middlebrook 7H9 medium followed by Western blot analy 
sis, using antiserum from clinically infected cows, revealed a 
42 kDa protein which may be specific for M. paratuberculosis 
(White et al., Am. J. Vet. Res., 55:1399-1405, 1994). Using the 
same methodology, AHPC gene products were identified that 
may be antigenic (Hsieh et al., Proceed. Fifth Intl. Colloq. 
Paratuberculosis, Chiodini et al., eds., 1997, pp. 82-87). 
M. paratuberculosis antigens that have been cloned 
include the heat shock proteins HSP65 and HSP70, the trans 
posase form IS900, a putative serine protease, bacteriofer 
ritin, the 34 kDa antigen bearing major B cell epitopes (re 
viewed by Stevenson and Sharp, Vet. J. 153:269-286, 1997), 
and more recently, the 35 kDa antigen (El Zaatari et al., J. 
Clin. Microbiol. 35:1794-1799, 1997) and the fled protein 
from IS900 (Doran et al., Microbiol. 143:547-552, 1997). In 
addition, a novel extracellular ferric reductase enzyme activ 
ity with a potential role in the evasion of intracellular defense 
mechanisms has been identified (Homuth et al. Infect. 
Immun., 66:710-716, 1998). Secreted proteins of M. paratu 
berculosis have received attention as potential immune tar 
gets early in infection. Some of these proteins are present as 
glyconjugates and different epitopes in the glycosylated and 
non-glycosylated moieties seem to be recognized in cattle 
and sheep (Mutharia etal, Infect. Immun. 65:387-394, 1997). 
Diagnosis and control of paratuberculosis presents a sig 
nificant challenge. Although vaccination does reduce clinical 
signs of Johne's disease, it does not prevent losses in milk 
production (van Schaik et al., Vet. Rec., 139:624-627, 1996). 
Improved vaccines and diagnostic tools are urgently needed. 
Likewise faster, specific, and more accurate and sensitive 
diagnostics need to be developed, especially to detect animals 
in the early stages of the disease. These tools preferably 
should also be able to discriminate between vaccinated and 
infected animals. 
US 7,740,867 B2 
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Identification of M. paratuberculosis virulence determi 
nants is a critical step in developing Suitable methods of 
diagnosis and control, and requires a systematic method by 
which virulence determinants can be found. U.S. Pat. No. 
5,783.386 to Jacobs et al. describes a method for identifying 
virulence determinants of mycobacterial species involving 
the preparation of a genomic DNA library and constructing 
shuttle vectors containing inserts from the library con 
structed. These vectors are then used to transform a virulent 
organisms to form recombinants. Virulence determinants are 
identified by inoculating animals with the transformed 
recombinant organisms to select virulent recombinants and 
then identifying the DNA sequences that confer virulence. 
Cavaignac, et al. (Arch. Microbial. 173:229-231, 2000) stud 
ied virulence mechanisms in M. paratuberculosis by the 
introduction of random mutants using transposon mutagen 
esis. Two thousand mutants were screened on the basis of 
auxotrophy and altered cell wall. Pelicic et al. (U.S. Pat. No. 
6,096,549) disclose a method for inserting a transposon into a 
mycobacterium strain using a vector containing the sacB 
gene. Use of this vector to identify virulence determinants is 
also disclosed. The present disclosure teaches an alternative 
method utilizing transposon mediated mutation and positive 
selection of mutants by antimicrobial agents that kill growing 
mycobacteria. 
BRIEF SUMMARY OF THE INVENTION 
Among the several aspects of the invention is provided a 
method for identifying virulence determinants of a bacteria 
comprising introducing at least one mutation into the genome 
of a bacteria; culturing the mutated bacteria in the presence of 
an antimicrobial agent that kills growing but not non-growing 
bacteria; selecting Surviving bacteria; testing the selected Sur 
viving bacteria for virulence; selecting the non virulent bac 
teria; sequencing genetic material from the selected non viru 
lent bacteria; determining the site of mutation; and comparing 
the sequence at the mutated site to the corresponding wild 
type Sequence. 
Another aspect provides a composition for immunizing an 
animal against bacterial infection comprising a pharmaceuti 
cally acceptable carrier, diluent or excipient; and at least one 
non-virulent strain of bacteria produced by the process com 
prising introducing at least one mutation into the genome of a 
bacteria; culturing the mutated bacteria in the presence of an 
antimicrobial agent that kills growing but not non-growing 
bacteria; selecting Surviving bacteria; testing the selected Sur 
viving bacteria for virulence; and selecting the non-virulent 
strains. 
Still another aspect provides a composition for immuniz 
ing an animal against a bacteria comprising a pharmaceuti 
cally acceptable carrier diluent or excipient; and at least one 
bacterial virulence determinant, the determinant identified by 
a process comprising; introducing at least one mutation into 
the genome of a bacteria; culturing the mutated bacteria in the 
presence of an antimicrobial agent that kills growing but not 
non-growing bacteria; selecting Surviving bacteria; testing 
the selected surviving bacteria for virulence; selecting the 
non-virulent strains; sequencing genetic material from the 
selected non-virulent bacteria to determine the site of the 
mutation; and identifying the virulence determinant based on 
the site of the mutation. 
Yet another aspect provides a method for inducing an 
immune response in an animal against a bacteria comprising 
administering to an animal an immune response inducing 
amount of any of the previously described compositions. 
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Another aspect provides a method for diagnosing infection 
by Mycobacterium paratuberculosis comprising obtaining a 
sample from an animal and determining the presence or 
absence in the sample of a bacterial virulence determinant, 
said determinant identified by the methods described above. 
BRIEF DESCRIPTION OF THE DRAWINGS 
These and other features, aspects, and advantages of the 
present invention will become better understood with regard 
to the following description, appended claims and accompa 
nying figures where: 
FIG. 1 shows Southern blot analysis of M. paratuberculo 
sis K-10 true transposon mutants. 
FIG. 2 shows the location of the BETH-R and BETH-F 
primers in the Tn5367 on and partial results of sequencing. 
Also shown is the alignment of nucleotide sequence obtained 
from mutant GPM207 (SEQ ID NO: 5) using BETH-F and 
the xerC gene (GenBank No. Z97369) (SEQID NO: 6). 
FIG. 3 shows the effects of co-culture with either Bay y 
3118 or D-cycloserine on growing and non-growing M. 
paratuberculosis strain K-10 in complete Middlebrook 7H9 
medium. 
ABBREVIATIONS AND DEFINITIONS 
cfu colony forming unit 
pful plaque forming unit 
MIC-minimal inhibitory concentration 
Albumin dextrose complex’ means 2 g glucose, 5 g 
bovine serum albumin fraction V and 0.85g NaCl in 100 mL 
deionized water. 
As used herein “polynucleotide' and "oligonucleotide' are 
used interchangeably and refer to a polymeric (2 or more 
monomers) form of nucleotides of any length, either ribo 
nucleotides or deoxyribonucleotides. Although nucleotides 
are usually joined by phosphodiester linkages, the term also 
includes polymeric nucleotides containing neutral amide 
backbone linkages composed of aminoethyl glycine units. 
This term refers only to the primary structure of the molecule. 
Thus, this term includes double- and single-stranded DNA 
and RNA. It also includes known types of modifications for 
example, labels, methylation, "caps'. Substitution of one or 
more of the naturally occurring nucleotides with an analog, 
internucleotide modifications such as, for example, those 
with uncharged linkages (e.g., methyl phosphonates, phos 
photriesters, phosphoamidates, carbamates, etc.), those con 
taining pendant moieties, such as, for example, proteins (in 
cluding for e.g., nucleases, toxins, antibodies, signal 
peptides, poly-L-lysine, etc.), those with intercalators (e.g., 
acridine, psoralen, etc.), those containing chelators (e.g., met 
als, radioactive metals, boron, oxidative metals, etc.), those 
containing alkylators, those with modified linkages (e.g., 
alpha anomeric nucleic acids, etc.), as well as unmodified 
fowls of the polynucleotide. Polynucleotides include both 
sense and antisense Strands. 
As used herein “polypeptide”, “protein’ and "peptide' are 
used interchangeably and refer to a polymer of two or more 
amino acids. Included within the definition are polypeptides 
containing one or more analogs of an amino acid, including, 
for example, unnatural amino acids, polypeptides with Sub 
stituted linkages, as well as modifications known in the art, 
both naturally occurring and non-naturally occurring. 
As used herein, the term “animal' includes human beings. 
As used herein, the term “patient' includes humans and 
animals. 
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DETAILED DESCRIPTION OF PREFERRED 
EMBODIMENT 
The following detailed description is provided to aid those 
skilled in the art in practicing the present invention. Even So, 
this detailed description should not be construed to unduly 
limit the present invention as modifications and variations in 
the embodiments discussed herein can be made by those of 
ordinary skill in the art without departing from the spirit or 
Scope of the present inventive discovery. 
All publications, patents, patent applications, databases 
and other references cited in this application are herein incor 
porated by reference in their entirety as if each individual 
publication, patent, patent application, database or other ref 
erence were specifically and individually indicated to be 
incorporated by reference. 
The present invention relates to the method for identifica 
tion of virulence determinants in bacteria particularly in 
members of the genus Mycobacterium. The genus Mycobac 
terium includes the species M. phlei, M. Smegmatis, M. afri 
canum, M. fortuitum, M. marinum, M. ulcerans, M. tubercu 
losis, M. bovis, M. microti, M. avium, M. paratuberculosis, M. 
leprae, M. lepraemurium, M. intracellulare, M. Scrofiulla 
ceum, M. xenopi, M. genavense, M. kansasii, M. Simiae, M. 
Szulgai, M. haemophylum, M. asiaticum, M. amlimoense, and 
M. Shimoidei. In one embodiment, the mycobacteria are slow 
growing mycobacteria. Any virulent strain of a species of 
mycobacterium that is slow growing and capable of being 
maintained in vitro can be used in the practice of the present 
invention. Examples of slow growing mycobacteria include 
M. tuberculosis, M. bovis, M. africanum, M. marinum, M. 
avium, and M. paratuberculosis. In one embodiment, strains 
of M. paratuberculosis are used and in particular the virulent 
strain K-10 of M. paratuberculosis. 
Once a particular strain or strains has been chosen, muta 
tions are introduced into the genome of the selected bacteria. 
Numerous means for inserting mutations into the genome of 
bacteria are known in the art and can be found in standard 
references such as Sambrook et al. Molecular Cloning, 2nd 
ed., Cold Spring Harbor Press, 1989 and Ausubel et al., Short 
Protocols in Molecular Biology, 3rd ed., Wiley, 1995. A dis 
cussion of methods of mutagenesis directed particularly to 
mycobacteria can be found in Jacobs et al., Methods in Enzy 
mology, 204:537-555, 1991 and Pelicic et al., Molec. Micro 
biol., 28:413-420, 1998. Mutations introduced can be site 
directed to a particular gene or sequence of interest, or the 
location of the mutations can be random. Ifrandom mutation 
is used, it is preferred that the mutations be approximately 
evenly distributed throughout the genome. Two particularly 
useful forms of mutagenesis are allelic exchange mutagenesis 
and transposon mutagenesis although other forms of 
mutagenesis Such as chemical and enzymatic (e.g. restriction 
enzyme mediated integration) mutagenesis can be used. 
In allelic exchange mutagenesis, the gene or sequence of 
interest is disrupted using homologous recombination Such 
that the functional allele is replaced with an inactivated copy. 
Following introduction of the inactivated copy, the virulence 
of the transformed bacteria can be compared to the parental 
strain. The efficiency of allelic exchange mutation is 
improved through the use of counter selection strategies 
which eliminate transformants retaining the delivery vector. 
Successful allelic exchange mutations have been achieved in 
mycobacteria (U.S. Pat. No. 6,096,549; Balasubramanian et 
al., J Bacterol. 178:273-279, 1996; McFadden. Molec. Micro 
biol., 21:205-211, 1996: Pelicic et al., Proc. Natl. Acad. Sci. 
USA, 94:10955-10960, 1997). 
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In one embodiment, the introduction of mutations is by 
transposon mutagenesis. Transposon mutagenesis occurs by 
the insertion of a mobile element called a transposon into the 
gene or sequence of interest, thus disrupting its function. An 
advantage of transposon mutagenesis is that no previous 
assumptions need to be made regarding the identity of the 
gene or sequence to be disrupted. In general, a transposon 
contains an inverted repeat sequence at the 5' and 3' ends and 
a gene or genes encoding transposase enzyme(s) between the 
inverted repeats. In transposon mutagenesis, the transposon is 
removed from a vector and inserted or transposed into the 
chromosome of a bacteria to be mutated. As used herein, the 
term “transposon’ is a general term and encompasses both 
non-mutated and mutated transposons. Thus, the term 
includes transposons in which a portion of the nucleotide 
sequence has been deleted and/or replaced, and/or wherein 
the transposon contains additional DNA sequences. Transpo 
son mutagenesis has been Successfully used in mycobacteria 
(Martin et al., Nature, 345:739-743, 1990; Guilhot et al., J 
Bacteriol. 176:535-539, 1994; Pelicic et al., Proc. Natl. Acad. 
Sci USA, 94:10955-10960, 1997: Bardarov et al., Proc. Natl. 
Acad. Sci. USA, 94:10961-10966, 1997). In one preferred 
embodiment, transposon mutagenesis is accomplished by use 
of the transposable element Tn5367, a single-unit transposon 
which carries a kanamycin-resistance marker and the M. 
Smegmatis insertion sequence IS 1096 (Cirillo et al., J. Bacte 
rol. 173:7772-7780, 1991; McAdam et al., Infect. Immunol., 
1004-1012, 1995). 
Introduction of vectors useful in the practice of the present 
invention can be accomplished by any suitable method known 
in the art. Various methods are known for the introduction of 
DNA into bacterial cells and include, for example, calcium 
phosphate transfection, DEAE-dextran mediated transfec 
tion, Polybrene, protoplast fusion, liposomes, phage infec 
tion, conjugation, and electroporation. Commonly, introduc 
tion of vectors for allelic exchange or transposon mutagenesis 
in mycobacteria is by either electroporation or phage infec 
tion. In one preferred embodiment, introduction of the DNA 
is by phage infection and in particular by the use of the TM4 
thermosensitive transposon delivery shuttle plasmid phaE94 
(Bardarov et al. Proc. Natl. Acad. Sci. USA,94:10961-10966, 
1997). 
In general, a shuttle plasmid comprises a bacteriophage 
DNA into which a plasmid sequence has been inserted into a 
nonessential region. In one embodiment, the bacteriophage is 
from a mycobacteriophage and the plasmid sequence is a 
cosmid sequence, preferably an E. coli cosmid sequence. 
Shuttle plasmids can, therefore, replicate in bacteria as a 
plasmid/cosmid or as a phage. The inserted plasmid/cosmid 
DNA is preferably flanked by restriction sites not found in the 
bacteriophage DNA, so that the inserted DNA can be easily 
excised. In one embodiment, a cosmid containing a transpo 
son is obtained and inserted into the bacteriophage backbone 
using standard methods of cosmid cloning (Sambrook et al., 
Molecular Cloning, 2nd ed., Cold Spring Harbor Press, 
1989). 
The sequence containing the transposon can, and usually 
does, also contain a selection marker sequence. Typically, this 
sequence encodes a protein necessary for the Survival or 
growth of the host cell transformed with the shuttle plasmid. 
Examples of suitable markers for prokaryotic cells include 
tetracycline, kanamycin, and amplicillin resistance. 
In one embodiment, the shuttle plasmid is a temperature 
sensitive plasmid. Temperature sensitive shuttle plasmids are 
those which replicate and form plaques at a permissive tem 
perature, but do not undergo a lytic cycle and so do not form 
plaques at a non-permissive temperature. 
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Once the temperature sensitive shuttle plasmid has been 
produced it can be introduced into a bacterial host which will 
allow growth of the shuttle plasmid as alytic bacteriophage at 
a permissive temperature. Introduction of the shuttle plasmid 
into the host cell can be by any method suitable for the 
introduction of DNA into a bacterial host including those 
discussed above. Introduction of the shuttle plasmid and cul 
ture at a permissive temperature results in the production of 
large numbers of bacteriophage particles. The bacteriophages 
are isolated using standard techniques and then used to infect 
Susceptible bacteria at a non permissive temperature. At the 
non-permissive temperature, rather than causing lysis of the 
infected bacteria, the shuttle plasmid gives rise to bacterial 
transductants which can then be selected on the basis of a 
selection marker, if present. 
In one preferred embodiment, introduction of the DNA is 
by the use of the TM4 thermosensitive transposon delivery 
shuttle plasmid phaE94 (Bardarov et al. Proc. Natl. Acad. 
Sci. USA, 94:10961-10966, 1997). This shuttle plasmid con 
tains the transposon Tn5367 which is a derivative of the 
insertion sequence IS1096 from M. Smegmatis and carries the 
aph gene conferring kanamycin resistance. In this embodi 
ment, phaE94 is propagated in M. Smegmatis at a permissive 
temperature and the resulting mycobacteriophage used to 
infect Susceptible mycobacteria at a non-permissive tempera 
ture. Mycobacteria undergoing transformation are then 
selected by kanamycin resistance. 
Once one or more mutations have been introduced into the 
genome, a selection method is employed in order to select 
those bacteria which the mutation has disrupted a gene or 
nucleic acid sequence potentially involved in virulence. Vari 
ous methods can be employed to determine virulence. For 
example, Suitable host animals can be inoculated with the 
mutated bacteria and monitored for development of disease 
symptoms and/or replication of the organisms injected. Alter 
natively, selection can be based on the use of a chemical, and 
in particular, an antimicrobial, the effect of which is associ 
ated with a trait related to virulence. Since bacterial growth is 
a necessary part of virulence, in one embodiment the selec 
tion is based on the ability of an antimicrobial to kill growing 
mycobacteria while having a reduced or no effect on non 
growing bacteria. Thus, antimicrobials that interfere with 
processes involved in bacterial growth and in particular DNA 
replication are preferred. Although not necessary to practice 
the present invention, it is preferred that the antimicrobial 
agent used be able to enter eukaryotic cells, thus allowing 
screening of transformed bacteria in intracellular culture sys 
tems, e.g. macrophage culture. In one embodiment, the anti 
microbial is a quinolone. In another embodiment, the antimi 
crobial is a fluoroquinolone. In yet another embodiment, the 
antimicrobial is Bayy 31 18. Bayy 3118 has been reported to 
kill growing but not non-growing Mycobacterium avium 
within human macrophages (Bermudez et al., FEMS Micro 
bial. Lett. 1787:19-26, 1999). In still another embodiment, 
the antimicrobial is D-cycloserine (Cáceres et al., J. Bacte 
riol. 179:5046-5055, 1997). 
The exact amount of the antimicrobial used will vary with 
the particular Substance and organism in question. In general, 
the concentration of the antimicrobial should exceed the 
approximate minimal inhibitory concentration (MIC) for the 
particular organism being studied. Determination of MIC is 
routine in the art and can be accomplished by the skilled 
technician without undue experimentation. In one embodi 
ment, in which M. paratuberculosis strain K-10 and Bay y 
31 18 are used, the MIC is approximately 0.015 lug/mL. In 
another embodiment, the concentration of Bay y 3118 is 5x 
the MIC. In still another embodiment in which M. paratuber 
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culosis strain K-10 and D-cycloserine are used the MIC is 
approximately 25 ug/mL. In yet another embodiment, the 
concentration of D-cycloserine is 5x the MIC. 
In general, Screening is accomplished by culturing the 
mutated bacteria in the presence of the antimicrobial agent. 
As will be apparent to those skilled in the art, the exact culture 
conditions will vary with the organism being studied. When 
M. paratuberculosis is used, either broth or macrophage cul 
ture can be used. Methods for the culture of mycobacteria are 
well known in the art and can be found, for example, in Jacobs 
et al., Methods in Enzymology, 204:537-555, 1991: Foley 
Thomas et al. Microbiology 141:1173-1181, 1995; and Wil 
liams et al., J. Clin. Microbiol. 37:304-309, 1999. In one 
embodiment, mycobacteria are grown in Middlebrook 7H9 
broth. As is known in the art and described in the references 
cited above, Middlebrook 7H9 broth is supplemented 
depending on the particular species of mycobacteria cultured. 
Alternatively, an intracellular culture system such as a mac 
rophage or amoeba (Cirillo et al., Infect. Immunol. 65:3759 
3767, 1997) culture system can be used. Mycobacteria natu 
rally infect macrophages as part of the disease process. Thus, 
mycobacteria can be cultured in macrophages. In this system, 
mycobacteria, preferably in a single cell Suspension, are 
added to a culture of macrophages from a suitable species. 
The macrophages used can be recently collected from blood 
using known, standard methods or can be from a macrophage 
cell line. The mycobacteria are allowed to infect the macroph 
ages. The infected macrophages are then maintained under 
suitable culture conditions so that the mycobacteria survive 
and grow within the macrophages. 
The antimicrobial selection agent is added to the culture 
system at a concentration that exceeds the MIC and the cul 
ture continued for a period of time sufficient to kill the mul 
tiplying bacteria. It will be apparent to those skilled in the art 
that the exact amount of time required will vary with such 
well known factors as the amount and type of selection agent 
used, the culture system, and the species of mycobacteria. In 
general, the selection conditions can be optimized by cultur 
ing bacteria for various times and at various concentrations of 
antimicrobials to determine the combination of times and 
concentrations which effectively kill growing, but not non 
growing bacteria. Such optimization can readily be achieved 
by the skilled technician without undue experimentation. 
After the selection period, the surviving bacteria are col 
lected, individual bacteria isolated, by for example clonal 
streaking, and the clones expanded using standard culture 
methods. If desired following expansion, the selected bacteria 
can be further characterized by genetic, biochemical, and 
animal testing. 
Characterization can include determination of whether the 
transposon has been incorporated into the genome. This can 
be accomplished using well known techniques such as South 
ern blotting, dot or slot blots, and in situ hybridization to 
bacterial chromosomes, using a polynucleotide probe com 
plimentary to the transposon used. Information regarding the 
location of the transposition and the gene or sequence dis 
rupted can be obtained by sequencing. In general, this can be 
accomplished by obtaining purified genomic DNA from 
transfected bacteria and cutting the DNA with restriction 
enzymes that do not cut within the transposon. The restriction 
fragments obtained can be cloned into a cloning vector using 
standard techniques and amplified for sequencing. Any 
known method of sequencing can be used. In one embodi 
ment, sequencing is accomplished by cycle sequencing out 
ward from the transposon. Once the sequence information has 
been obtained, the nucleic acid sequences or deduced amino 
acid sequences can be compared to sequences in publicly 
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Center for Biotechnology Information at http://www.ncbi.n- 
lm.nih.gov/, the European Bioinformatics Institute at http:// 
www.ebi.ac.uk/, The Institute for Genomic Researchat http:// 
www.tigr.org, The Sanger Centreat http://www.sanger.ac.uk/ 
Projects/. The Computational Biology Center of the 
University of Minnesota Microbial Genome Project at http:// 
cbc.umn.edu/, and the Institute Pasteur at http://genolist.pas 
teur.fr/. Based on sequence homology, the identity of the gene 
or sequence disrupted by the insertion can be determined and 
thus the virulence determinant identified. 
Alternatively or additionally information can be obtained 
by biochemical studies, especially by auxotrophic analysis. 
Auxotrophic mutants are mutants that require a nutrient or 
Substance not required by the parent organism from which the 
mutant was derived. Determination of auxotrophic mutants 
can be made by comparing growth on complete and incom 
plete growth medium. For those mutants showing no or 
reduced growth on incomplete medium, the missing nutrients 
can be individually added back until growth comparable to 
that seen with complete medium is obtained. Methods for 
selecting auxotrophic mutants are well known in the art and 
can be accomplished by the skilled technician without undue 
experimentation. 
Whether the selected mutants lack virulence can be tested 
by inoculating Susceptible animals with the selected organ 
ism and determining if the organism results in clinical Symp 
toms or if the organism multiples and spreads beyond the site 
of inoculation. The animal inoculated can be the natural host 
for the organism or it can be a animal model. In one embodi 
ment, the mouse model and in particular the beige mouse 
(Whipple et al. Proc. 3rd Intl. Colloq Paratuberculosis, Intl. 
Assn. Paratuberculosis, pp. 551-552) is used for virulence 
testing. In general, the animal is inoculated with a quantity of 
the organism Sufficient to result in infection. Inoculation can 
be oral, parenteral or any other suitable method. The exact 
amount of the organism inoculated will vary with well known 
factors such as the species, size and age-of the animal. Deter 
mination of the proper quantity of organism to be adminis 
tered can be determined by one of ordinary skill in the art 
without undue experimentation. At various times after inocu 
lation, the animals are sacrificed and various organs examined 
for the presence of the organism. If the organism is not 
detected, it can be assumed that the gene or sequence dis 
rupted is a virulence determinant. 
Confirmation that the sequence identified is a virulence 
determinant can be obtained by a complementation study. In 
a complementation study, the wild type sequence is reintro 
duced into the mutated organism, for example by introduction 
of an expression vector, and the effect on virulence deter 
mined. If the disrupted sequence is associated with virulence, 
replacement of the sequence should restore virulence. Ingen 
eral, the disrupted gene or sequence is inserted into a suitable 
expression vector using standard techniques in molecular 
biology found in standard references and described herein. 
The expression vector is then introduced into the mutant 
organism and the virulence of the complemented organism is 
tested as described above. 
The method of the present invention can be used to create 
strains of mycobacteria which are non-virulent or have 
reduced virulence. As used herein the term attenuated refers 
to mutated Strains whose virulence is reduced as compared to 
the same organism in its non-mutated form. Such attenuated 
mycobacteria can be used in compositions for the treatment 
and/or prophylaxis of diseases caused by or associated with 
the organism. This includes compositions designed to stimu 
late an immune response against a organism, for example, a 
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vaccine. Attenuated strains produced by the method of the 
present invention are thought to be particularly useful 
because they make it possible to differentiate between indi 
viduals who test positive for the presence of mycobacteria 
due to vaccination or natural infection based on the presence 
of the introduced transposon. 
Likewise, polypeptides encoded by sequences identified 
by the method of the present invention as being involved in 
virulence can be used to stimulate an immune response in an 
animal. In this embodiment, the sequence identified as 
described herein is placed into an expression vector. If 
desired, the polypeptide sequence identified can be fused or 
assembled with additional amino acids to form a fusion pro 
tein. Such fusion proteins can be used to increase the solubil 
ity or antigenicity of the virulence polypeptide. Methods for 
the production of fusion proteins are well known in the art and 
can be found in standard molecular biology references. The 
expression vector is, in turned, introduced into a suitable 
prokaryotic or eukaryotic host cell and the encoded polypep 
tide expressed. The resulting polypeptide is then purified 
using standard biochemical techniques from lysates of the 
host cells or from culture medium containing the host cells. 
The compositions can be administered to any animal which 
can become infected with a species of mycobacteria. In one 
embodiment, the animal is a ruminant animal, more prefer 
ably a Bovidae and more preferably still a member of the 
genus Bos. When the composition comprises whole myco 
bacteria, the bacteria can be live or they can be killed by any 
Suitable means such as heating, chemical treatment, or dis 
ruption of the bacterial cell. Bacteria can be in a preserved 
state Such as in a lyophilized form which may or may not be 
reconstituted prior to administration. The compositions can 
comprise attenuated bacteria alone, virulence polypeptides 
alone, or a combination of attenuated bacteria and virulence 
polypeptides. 
The compositions of the present invention can be admin 
istered by a variety of routes and methods. Suitable routes and 
methods of administration include orally, parenterally, by 
inhalation spray, rectally intradermally, transdermally, or 
topically in dosage unit formulations containing conventional 
nontoxic pharmaceutically acceptable carriers, adjuvants, 
and vehicles as desired. The term parenteral as used herein 
includes subcutaneous, intravenous, intramuscular, or 
intrasternal injection, or infusion techniques. In one embodi 
ment, the complexes are administered by injection. In another 
embodiment, the compositions are administered orally. In yet 
another embodiment, the compositions are administered by 
inhalation. Methods for the formulation of drugs is well 
known in the art and is discussed in, for example, Hoover, 
John E., Remington's Pharmaceutical Sciences, Mack Pub 
lishing Co., Easton, Pa. (1975), and Liberman, H. A. and 
Lachman, L. Eds. Pharmaceutical Dosage Forms, Marcel 
Decker, New York, N.Y. (1980). 
Injectable preparations, for example, sterile injectable 
aqueous or oleaginous suspensions, can be formulated 
according to the known art using Suitable dispersing or wet 
ting agents and Suspending agents. The sterile injectable 
preparation may also be a sterile injectable solution or Sus 
pension in a nontoxic parenterally acceptable diluent or Sol 
vent, for example, as a solution in 1,3-butanediol. Among the 
acceptable vehicles and solvents that may be employed are 
water, Ringer's solution, and isotonic sodium chloride solu 
tion. In addition, Sterile, fixed oils are conventionally 
employed as a solvent or Suspending medium. For this pur 
pose, any bland fixed oil may be employed, including Syn 
thetic mono- or diglycerides. In addition, fatty acids Such as 
oleic acid are useful in the preparation of injectables. Dim 
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ethyl acetamide, Surfactants including ionic and non-ionic 
detergents, and polyethylene glycols can be used. Mixtures of 
Solvents and wetting agents such as those discussed above are 
also useful. 
Suppositories for rectal administration of the compositions 
discussed herein can be prepared by mixing the active agent 
with a suitable non-irritating excipient such as cocoa butter, 
synthetic mono-, di-, or triglycerides, fatty acids, or polyeth 
ylene glycols which are solid at ordinary temperatures, but 
liquid at the rectal temperature, and which will therefore melt 
in the rectum and release the composition. 
Solid dosage forms for oral administration may include 
capsules, tablets, pills, powders, and granules. In Such solid 
dosage forms, the compounds of this invention are ordinarily 
combined with one or more adjuvants appropriate to the 
indicated route of administration. If administered per os, the 
compounds can be admixed with lactose, Sucrose, starch 
powder, cellulose esters of alkanoic acids, cellulose alkyl 
esters, talc, Stearic acid, magnesium Stearate, magnesium 
oxide, Sodium and calcium salts of phosphoric and Sulfuric 
acids, gelatin, acaciagum, sodium alginate, polyvinylpyrroli 
done, and/or polyvinyl alcohol, and then tableted or encap 
Sulated for convenient administration. Such capsules or tab 
lets can contain a controlled-release formulation as can be 
provided in a dispersion of active compound in hydroxypro 
pylmethyl cellulose. In the case of capsules, tablets, and pills, 
the dosage forms can also comprise buffering agents such as 
Sodium citrate, or magnesium or calcium carbonate orbicar 
bonate. Tablets and pills can additionally be prepared with 
enteric coatings. 
For therapeutic purposes, formulations for parenteral 
administration can be in the form of aqueous or non-aqueous 
isotonic sterile injection Solutions or Suspensions. These solu 
tions and Suspensions can be prepared from Sterile powders or 
granules having one or more of the carriers or diluents men 
tioned for use in the formulations for oral administration. The 
compounds can be dissolved in water, polyethylene glycol, 
propylene glycol, ethanol, corn oil, cottonseed oil, peanut oil, 
sesame oil, benzyl alcohol, Sodium chloride, and/or various 
buffers. Other adjuvants and modes of administration are well 
and widely known in the pharmaceutical art. 
Liquid dosage forms for oral administration can include 
pharmaceutically acceptable emulsions, Solutions, Suspen 
sions, syrups, and elixirs containing inert diluents commonly 
used in the art, such as water. Such compositions can also 
comprise adjuvants, such as wetting agents, emulsifying and 
Suspending agents, and Sweetening, flavoring, and perfuming 
agents. 
The amount of attenuated organism and/or virulence deter 
minants that can be combined with the carrier materials to 
produce a single dosage form will vary depending upon the 
patient or animal and the particular mode of administration. 
Compositions of the present invention can be given as a single 
administration or in multiple administrations over a period of 
time. If desired, after the initial administration or series of 
administrations, additional periodic administrations (e.g. 
boosters) of the composition can be given. 
The attenuated organisms and/or virulence determinants 
can be administered in combination with a pharmaceutically 
acceptable immune system stimulant or adjuvant. Examples 
of Such immune system stimulants or adjuvants include, but 
are not limited to, Alum (aluminum phosphate or aluminum 
hydroxide), Freund's adjuvant, calcium phosphate, beryllium 
hydroxide, dimethyl dioctadecyl ammonium bromide, 
saponins, polyanions, e.g. poly A:U, Ouil A, inulin, 
lipopolysaccharide endotoxins, liposomes, lysolecithins, 
Zymosan, propionibacteria, mycobacteria, and cytokines, 
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Such as, interleukin-1, interleukin-2, interleukin-4, interleu 
kin-6, interleukin-12, interferon-C, interferon-Y, granulo 
cyte-colony Stimulating factor. 
In another embodiment, the virulence determinants iden 
tified by the method of the present invention are used for 
diagnosis of mycobacterial infection. Biological samples can 
be obtained from a subject suspected of suffering from a 
mycobacterial infection. Biological samples include any 
sample of tissue or fluid isolated from an individual. 
Examples of biological samples, include, but are not limited 
to plasma, serum, spinal fluid, lymph fluid, sections of skin, 
respiratory, intestinal, and genitourinary tracts, tears, saliva, 
mucus, milk, blood cells, tumors, tumor cells, and organs. 
Biological samples also include samples obtained from in 
vitro cell culture, for example, cells grown in culture, includ 
ing putatively infected cells and recombinant cells, cell com 
ponents, and conditioned media resulting from the culture of 
cells in culture medium. 
In one embodiment, diagnosis is made based on the pres 
ence of polynucleotide sequences identified by the method of 
the present invention. In this embodiment, a biological 
sample which contains nucleic acids is obtained from an 
individual. Polynucleotides whether in the form of DNA or 
RNA are obtained from the sample using well established 
techniques which are known to those in the art and can be 
found instandard molecular biology references. Such as those 
cited herein. In one embodiment, diagnosis is made based on 
hybridization of specific polynucleotide probes to sequences 
encoding virulence determinants identified by the present 
invention. Probes should be of sufficient length to provide 
specificity. In general, probes are at least 4 nucleotides in 
length, more preferably at least 8 nucleotides in length, even 
more preferably at least 12 nucleotides in length, and more 
preferably still at least 20 nucleotides in length. Probes used 
can be obtained from mycobacteria using standard methods, 
for example, by the use of restriction enzyme digestion to 
obtain Suitable nucleic acid fragments which are then inserted 
into a cloning vector, which is in turn introduced into a Suit 
able host cell. The host cells are then grown under conditions 
allowing replication of the cloning vector, and the desired 
sequences isolated and used as probes. Alternatively, probes 
can be produced by chemical synthesis in automated systems 
by any suitable method, for example, the phosphoramidite 
method of Beaucage and Carruthers (Teta. Letts., 22:1859 
1862, 198). When used for hybridization, it is desirable that 
the probes be completely complementary to the sequence to 
be detected, but probes which exhibit only partial comple 
mentarity can be used. Hybridization probes can, and often 
do, contain detection moieties. Such detection moieties 
include, but are not limited to radioactive labels, such as 
radionuclides, fluorophores or fluorochromes, peptides, 
enzymes, vitamins and steroids. 
In order to insure specificity hybridizations should be con 
ducted under highly stringent conditions. As is recognized in 
the art stringency is a combination of many factors such as 
temperature and the composition of the hybridization and 
wash solutions. Thus, many different conditions can result in 
the same degree of stringency. In general, highly stringent 
conditions are achieved by hybridization in a solution of 
6xSSC or SSPE at a temperature 20-25°C. below the melting 
temperature (T) for DNA-DNA hybrids and 10-15° C. 
below the T for DNA-RNA hybrids followed by washing in 
0.1 xSSC or SSPE at 42°C. Even higher stringency conditions 
can be achieved by washing in 0.1xSSC or SSPE at 50-65° C. 
In situations where the amount of nucleic acid which can be 
obtained from the sample is small, it may be desirable to 
amplify the sequences of interest by methods such as the 
US 7,740,867 B2 
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polymerase chain reaction (PCR), the ligase chain reaction 
(LCR) (see, Wu and Wallace, Genomics, 4:560-569, 1989; 
Landegren et al., Science, 241:1077-1080, 1988), transcrip 
tion amplification (Kwoh et al., Proc. Natl. Acad. Sci. USA, 
86: 1173-1177, 1989), self-sustained sequence replication 
(Guatelli et al., Proc. Natl. Acad. Sci. USA, 87: 1874-1878, 
1990), and nucleic acid based sequence amplification 
(NASBA). In one preferred embodiment, amplification is by 
PCR. Optimization of conditions for conducting PCR must 
be determined for each reaction and can be accomplished 
without undue experimentation by one of ordinary skill in the 
art. In general, methods for conducting PCR can be found in 
U.S. Pat. Nos. 4,965,188, 4,800,159, 4,683.202, and 4,683, 
195; Ausbel et al., eds. Short Protocols in Molecular Biology, 
3" ed., Wiley, 1995; and Innis et al., eds. PCR Protocols, 
Academic Press, 1990. 
Diagnosis of infection by the presence of sequences iden 
tified by the method of the present invention can be achieved 
by visualization of PCR products of a characteristic size. 
Individuals testing positive due to natural infection can be 
differentiated from individuals who have received attenuated 
vaccine by the presence of the transposon which will result in 
an increase in the size of the amplification product. Alterna 
tively, the amplification products could be detected by hybrid 
ization to specific probes as described above. 
In another embodiment, diagnosis is made by detection of 
polypeptides encoded by the sequences identified by the 
method of the present invention. In one embodiment, Such 
detection is by an immunological assay. Various immunologi 
cal assays known in the art can be used, including but not 
limited to competitive and non-competitive assay systems 
using techniques such as radioimmunoassays, ELISA (en 
Zyme linked immunosorbent assay), 'sandwich’ immunoas 
says, immunoradiometric assays, gel diffusion precipitin 
reactions, immunodiffusion assays, in vivo immunoassays 
(using colloidal gold, enzyme or radioisotope labels, for 
example), western blots, immunoprecipitation reactions, 
agglutination assays (e.g., gel agglutination assays, hemag 
glutination assays), complement fixation assays, immunof 
luorescence assays, protein A assays, and immunoelectro 
phoresis assays, etc. In one embodiment, antibody binding is 
detected by detecting a label on the primary antibody. In 
another embodiment, the primary antibody is detected by 
detecting binding of a secondary antibody or reagent to the 
primary antibody. In a further embodiment, the secondary 
antibody is labeled. 
Antibodies, either polyclonal or monoclonal, against 
polypeptides identified by the method of the present invention 
for use in immunological assays can be produced by known 
methods. If polyclonal antibodies are desired, an animal is 
immunized with a virulence polypeptide identified by the 
method of the present invention. The composition used for 
immunization can comprise the polypeptide alone or may 
further comprise an adjuvant or other immune system stimu 
lant. Further, the polypeptide can be conjugated to a carrier 
molecule or be part of a fusion protein in order to increase 
antigenicity. Following immunization, serum is collected 
from the immunized animals and treated according to well 
established methods. If desired, the antibody can be purified 
using known techniques such as affinity chromatography. 
Methods for the production of polyclonal antibodies are well 
known in the art and can be found for example in Ausubel et 
al., Short Protocols in Molecular Biology, 3rd ed. Wiley, 
1995. 
Likewise, monoclonal antibodies can be produced using 
well known techniques. In general, immortal antibody pro 
ducing cell lines are created by cell fusion, direct transforma 
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tion of B lymphocytes with oncogenic DNA, or transfection 
of Epstein-Barr virus. Panels of hybridomas can then be 
screened for the production of suitable monoclonal antibod 
ies using standard techniques. Methods for the production of 
monoclonal antibodies are well known in the art and can be 
found for example in U.S. Pat. Nos. 4.341,761; 4,399,121: 
4,427,783; 4,444,887; 4,466,917; 4,472,500; 4,491,632; and 
4493,890. 
Also encompassed by the present invention are diagnostic 
kits. Such kits can contain probes, primers and/or antibodies 
for the detection of polynucleotides or polypeptides identified 
by the method of the present invention. The probes, primers 
and antibodies may, optionally, incorporate a detection moi 
ety such as those described herein. The kits may further 
comprise buffers, reagents and instructions necessary for the 
use of the contents of the kits to detect the presence of the 
polynucleotides and/or polypeptides. 
EXAMPLES 
Example 1 
Bacterial Strains, Growth Conditions, and 
Recombinant DNA 
A virulent clinical isolate of M. paratuberculosis (strain 
K-10) was used. M. paratuberculosis cultures were grown 
standing at 37°C. in a complete growth medium comprising 
Middlebrook 7H9 broth enriched with oleic acid albumin 
dextrose complex, 0.4% casamino acids containing vitamins 
40 ug/mL L-tryptophan, 0.5 ug/mL mycobactin J (Allied 
Monitor, Fayette, Mo.), and 0.05% Tween 80. Escherichia 
coli DH5C. cells, used as cloning hosts were grown on Luria 
Bertani (LB) agar or broth supplemented with 50 ug/mL 
kanamycin. The conditionally replicating (temperature sen 
sitive) recombinant mycobacteriophage phaE94 (Bardarov 
et al., Proc. Natl. Acad. Sci. USA, 94:10961-10966, 1997) 
used to deliver the transposon Tn5367 (McAdam et al., Infect. 
Immun. 63:1004-1012, 1995) was propagated in Mycobacte 
rium smegmatis mc 155 at 30° C. as has been described 
previously. (Bardarov et al. Proc. Nat. Acad. Sci. USA, 
94:10961-10966, 1997). The transposon Tn5367 is a deriva 
tive of the insertion sequence IS1096 from M. Smegmatis and 
carries the aph gene conferring kanamycin resistance. 
Example 2 
Transposon Mutagenesis 
M. paratuberculosis cultures were grown to approximately 
1.5x10 cfu/mL (OD 0.38-0.75). Cultures (50 mL) were 
concentrated by centrifugation and resuspension in 1 mL of 
MP buffer (50 mM Tris-HCL, pH 7.6, 150 mL NaCl, 2 mM 
CaCl). Bacterial cells and phage were incubated at a non 
permissive temperature (37°C.) at the ratios and for the times 
indicted in Table 1. After completion of the adsorption time, 
2 mL of prewarmed stop buffer (MPbuffer containing 20 mM 
sodium citrate and 0.2% Tween 20) was added to prevent 
further phage infections. Kanamycin resistant (kan'olonies 
were selected on complete growth medium without Tween 
plus 15 g/Lagar containing 50 ug/mL, kanamycin at 37°C. In 
five independent experiments, 5,620 transductants were 
obtained (Table 1). In further experiments, the number of 
transductants was increased to 13,526. This provides a rep 
resentation of approximately 95% of the genome. Probability 
(%) values for the representation of the mutant pool were 
calculated using the formula ln(1-P)=Nxln(1-1/4500) 
US 7,740,867 B2 
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assuming a genome size of 5.0 Mb (allowing a 5% underes 
timation error for the reported size) and 4500 target genes and 
where N=13479 for P=95%. 
To verify that transposition events had occurred in these 
mutants, genomic DNA was isolated using standard tech 
niques (Sambrook et al., Molecular Cloning, 2nd ed., Cold 
Spring Harbor Press, 1989) and digested with PstI which does 
cleave the transposon. The digests were then hybridized over 
night understringent conditions of 65°C. in Rapid-hybbuffer 
(Amersham-Pharmacia, Piscataway, N.J.) using radiolabeled 
plasmid pYUB285 which carries the transposon as a probe 
followed by two, 20 minute washes in 2xSSC at 28°C., a 15 
minutes washin 0.5xSSC at 65° C. and a final 15 minute wash 
in 0.1 xSSC at 65° C. Each mutant gave, as expected, one 
hybridizable band with at least four distinct sizes observed 
(FIG. 1). This confirmed that transpositions had occurred and 
that each transformant represented transpositions at different 
chromosomal locations. Furthermore all mutants gave the 
same pattern of IS900 hybridizable bands as expected for 
derivatives of strain K-10, and none of the samples hybridized 
with TM4 DNA indicating that hybridization was not due to 
the residual presence of vector phage DNA. 
Example 3 
Subcloning and DNA Sequencing 
Chromosomal DNA from transposon mutant GPM207 and 
pACYC184 vector DNA was digested with EcoRI, ligated 
into the corresponding EcoRI site in the paCYC184 vector 
and transformed into E. coli DH5O. cells by using standard 
methods (Ausubel et al., Short Protocols in Molecular Biol 
ogy, 3rd ed., Wiley 1995). E. coli were cultured as described 
above and kanamycin resistant transformants isolated. Plas 
mid DNA was isolated from selected transformants and sub 
jected to automated sequencing using the BigDye Terminator 
Cycle Sequencing Ready Reaction (Perkin Elmer) and the 
ABI Prism 310 Genetic Analyzer (Perkin Elmer). Chromo 
Somal DNA sequences at the junctions of the transposon 
insertions were obtained by cycle sequencing outward from 
the transposon using the primers 5'-GGTCAGCGCAGGC 
GAAGCCC (BETH-F, SEQID NO: 1) and 5'-GCCAGGTC 
CACACTGCCCCC (BETH-R, SEQ ID NO: 2). The results 
are shown in FIG. 2. An 8 by duplication was observed at the 
transposon-chromosomal junction (SEQ ID NOS: 3 & 4) 
(FIG. 2). This duplication was also reported by Pelicic et al. 
(Proc. Natl. Acad. Sci. USA, 94:10955-10960, 1997) for 
transpositions of this element into five different genes in M. 
bovis BCG. The nucleotide sequence derived from BETH-F 
was translated based on the mycobacterial codon usage. A 
BLAST search identified the chromosomal gene carrying the 
transposon insertion as homologous to the M. leprae XerC 
gene (GenBank No. Z97369; SEQ 113 NO: 6) encoding a 
putative integrase/recombinase (52% identity and 63% simi 
larity for the region sequenced, see FIG. 2). 
Example 4 
Susceptibility of Growing and Non-Growing 
Populations of M. paratuberculosis in Broth Culture 
to Antimicrobial Agents 
Antimicrobial agents (antibiotics) tested were the fluoro 
quinolone Bay y 3118, and D-cycloserine. The aminoglyco 
side amikacin which kills both growing and non-growing M. 
paratuberculosis, was included as a control. M. paratubercu 
losis strain K-10 was grown in complete Middlebrook 7H9 
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medium containing mycobactin J as described above to an 
optical density (ODoo) of 0.3 to 0.4. For non growing con 
ditions, cells (200 ml) were harvested at room temperature, 
washed in MSS (Middlebrook 7H9 salt solution: 1.0 g/L 
KHPO, 0.05 g/L MgSO. NHSO, 2.5 g/L NaHPO, 
0.0005 g/L CaCl, 0.001 g/L ZnSO and 0.001 g/L CuSO), 
and resuspended in MSS as a single-cell suspension (Will 
iams et al., J. Clin. Microbiol. 37:304-309, 1999). Aliquots (10 ml at a cell density of 2x10 CFU/mL) were placed in 
sterile tissue culture flasks, and antibiotics were added at the 
following final concentrations Bay y 3118: 0.075 ug/mL 
(5xMIC) and 0.3 g/mL (20xMIC); D-cyloserine: 125ug/mL 
(5xMIC) and 500 ug/mL (20xMIC); amikacin: 10 ug/mL 
(5xMIC), and 40 ug/mL (20xMC). These cultures and a 
control without antibiotics (0x) were incubated at 37° C. and 
appropriate dilutions were plated in triplicate onto complete 
Middlebrook 7H9 medium at various time points. When these 
cells were inoculated into complete Middlebrook medium (growing conditions), they displayed normal growth (growth 
control). For growing conditions, cells were treated as 
described except that the growth control (Ox) was diluted 1:10 
and all cells were washed and resuspended in complete 
medium instead of MSS. The cells were also inoculated into 
MSS (no-growth control). 
The results are shown in FIG.3 and show that Bay y 3118 
at 5x the MIC does not kill non growing bacteria, but has a 
bactericidal action on growing bacteria. At both 5x and 20x 
the MIC, D-cycloserine had a moderate bactericidal effect on 
both growing and non growing bacteria. Amikcin, as 
expected, was bactericidal for both growing and non growing 
bacteria, but bacteria in stasis were particularly more Suscep 
tible. 
Example 5 
Susceptibility of Growing and Non-Growing 
Populations of M. paratuberculosis in Macrophage 
Culture to Antimicrobial Agents 
Bovine macrophages of the BOMAC line (Stabel and Sta 
bel, Vet. Immunol. Immunopathol. 45:211-220, 1995) are 
infected with single-cell Suspensions of mutated bacteria as 
described in Example 4 at a MOI of 10:1. Infected BOMAC 
cells are then incubated at 39°C. in RPMI-1640 tissue culture 
medium containing Bayy 31 18 at 5x the MIC for three days. 
After the incubation period, the infected BOMAC cells are 
lysed with 0.25% SDS and the viable bacteria recovered by 
centrifugation. These bacteria are used to infect a fresh cul 
ture of BOMAC cells, and this procedure is repeated until 
each pool of mutants has been passed 3 times through 
BOMAC cells. The bacteria recovered from the final passage 
and sample from earlier passages are then Subjected to 
molecular characterization as described in Example 3. 
Example 6 
Virulence Testing of M. paratuberculosis in 
Susceptible Mice 
Groups of 6 to 8 week old beige mice were infected orally 
with non mutated (wildtype) M. paratuberculosis strain K-10 
and euthanized at various times post infection. Bacterial loads 
in liver, spleen and ileum were determined. Intestinal wall 
tissue was fixed and stained with hematoxylin and eosin for 
histological assessment. Mice were given either a high infec 
tious dose of 5 doses of 1x10 bacteria administered on alter 
nate days (Experiment I) or a low infectious dose of 1x10' 
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bacteria in a single dose (Experiment II). The results are given 
in Table 2. With the high infectious dose, the bacteria contin 
ued to grow in the spleen during the 8-week period but bac 
terial load in the liver leveled off at three weeks. Effective 
18 
organism and a positive control group that receives the non 
mutated parental (wild type) strain from which the mutated 
organisms are derived. At various times after inoculation, 
animals are euthanized and bacterial loads in liver, spleen and 
multiplication during the 8-week period was also observed in 5 ileum are determined as described in Example 6. Mutant 
the terminal ileum with an in vivo generation time of about strains which do not show continued multiplication in tissues 
one week. These results showed that M. paratuberculosis can as compared to the corresponding controls are considered to 
infect beige mice through the intestinal mucosa. A higher be non-virulent. 
multiplication in the liver and spleen as compared to the 
ileum, however, indicated that the mice were experiencing a 10 Example 8 
systemic infection. Thus, using the high infectious dose, - 
mice infected with M. E. did not parallel Screening of Mutant Bacteria for Ability to 
all the features of ruminant paratuberculosis. Under the con- Stimulate Immunity 
ditions of Experiment II, the ileum displayed the greatest 
bacterial El multiplication Red in three is Mutant bacteria which have been found to be non virulent 
organs for the 8-week period. Thus, using a lower dose, oral by the method of Example 7 are tested tO determine their 
infection of beige mice with M. paratuberculosis followed a ability to stimulate immunity against subsequent infection 
course similar to the more time consuming monoassociated with non-mutated, virulent strains. Beige 1Ca inoculated 
nude mouse intragastric model (Hamilton et al., Vet Pathol. orally with mutant non-virulent strains as described in 
28:146-155, 1991). 2O Example 6. A second group of mice acts as a control group 
and receives only vehicle. At various times after inoculation, 
Example 7 mice are challenged with 1x10" bacteria of the non-mutated 
virulent parental strain. At various times after challenge mice 
Virulence Tested of Mutated Bacteria in Susceptible are euthanized and bacterial loads in liver, spleen and ileum 
Mice as are determined as described in Example 6. Mutated strains 
which are found to confer immunity are further tested to 
Beige mice are inoculated orally with a single dose of determine optimal dosage rates and methods of immuniza 
1x10" bacteria as described in Example 6. For each mutant tion, for example, single or multiple administration oral ver 
tested there is a test group of mice that receives the mutated Sus parenteral administration. 
TABLE 1 
Ads 
ODoo Ration Time Transd. Transp Kan P 
Expt. culture? PhB (hours) Freq. Freq mutants' N value 
I O48 2O 4 5.4x 108 1.0 x 10 1344 1344, 26% 
II O48 200 4 5.1 x 10' 9.8 x 107 1275 2619 42% 
III O.38 25 6 7.0 x 10 1.8 x 107 176 279S 46% 
IV O.38 25 24 5.4 x 10 1.4 x 107 136 2931 48% 
V 0.75 350 4 1.1 x 10' 3.6 x 10 2689 5620 71% 
'Experiment number 
*OD600m of M. paratuberculosis at harvest 
Ratio of phAE94PFU at 30°C. to the number of M. paratuberculosis K-10 CFU 
Adsorption time in hours at 37°C. 
Transduction frequency: number ofkanamycin-resistant colonies obtained at 37°C, perinfectingphage particle, 
Transposition frequency: number of kanamycin-resistant colonies obtained at 37°C, per recipient cell. 
"Total number of kanamycin-resistance colonies obtained at 37°C. (putative transposon mutants) 
Cumulativee number of kanamyucin-resistant colonies obtained 
'Probability (%) value for the representation of the mutant pool assuming randon transposition, 
TABLE 2 
CFU g (mean of all mice in group it SEM 
Liver 
Week I 
5.9 + 0.6 x 10' 
1.4 + 0.8 x 10 
2.5 + 0.4 x 10 
Not done 
2.9 + 0.6 x 10 
II 
7.9 + 0.4 x 10' 
1.5 + 0.5 x 10' 
Not done 
3.Ov0.2 x 10? 
1.1 + 0.6 x 10 
Spleen Ileum 
I II I II 
5.9 + 0.6 x 10 
2.2 + 0.2 x 10' 
Not done 
2.5 + 0.2 x 10' 
1.3 + 0.3 x 10' 
3.5 + 0.6 x 10' 
4.0 + 0.3 x 10' 
9.9 + 0.6 x 10' 
Not done 
2.2 + 0.3 x 10 
1...6+ 0.3 x 10° 
1.8 + 0.4 x 10? 
Not done 
1...6+ 0.3 x 10° 
5.9 + 0.4 x 10 
2.7+ 0.3 x 107 
1.1 + 0.4 x 108 
1.7 + 0.5 x 108 
Not done 
5.6+ 0.4 x 10 
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CONCLUSION 
In light of the detailed description of the invention and the 
examples presented above, it can be appreciated that the 
several aspects of the invention are achieved. 
It is to be understood that the present invention has been 
described in detail by way of illustration and example in order 
to acquaint others skilled in the art with the invention, its 
principles, and its practical application. Particular formula 
tions and processes of the present invention are not limited to 
the descriptions of the specific embodiments presented, but 
rather the descriptions and examples should be viewed in 
terms of the claims that follow and their equivalents. While 
SEQUENCE LISTING 
<16 Os NUMBER OF SEO ID NOS: 6 
<21 Oc 
<211 
<212> 
<213> 
<22 Os 
<223> 
SEO ID NO 1 
LENGTH: 2O 
TYPE: DNA 
ORGANISM: Artificial 
FEATURE; 
OTHER INFORMATION: Primer 
<4 OOs SEQUENCE: 1 
ggit cagcgca gg.cgaag.ccc 
SEO ID NO 2 
LENGTH: 2O 
TYPE: DNA 
ORGANISM: Artificial 
FEATURE; 
OTHER INFORMATION: Primer 
<4 OOs SEQUENCE: 2 
gcc aggt cca cactgcc ccc 
<21 Os SEQ ID NO 3 
&211s LENGTH: 19 
&212s. TYPE: DNA 
<213> ORGANISM: Mycobacterium smegmatis 
22 Os. FEATURE: 
<221s NAMEAKEY: misc feature 
<222s. LOCATION: (1) . . (19) 
<223> OTHER INFORMATION: Transposon 
<4 OOs SEQUENCE: 3 
tgttaacggg ct ctitcgca 
<21 Os SEQ ID NO 4 
&211s LENGTH: 19 
&212s. TYPE: DNA 
<213> ORGANISM: Mycobacterium smegmatis 
22 Os. FEATURE: 
<221s NAMEAKEY: misc feature 
<222s. LOCATION: (1) . . (19) 
<223> OTHER INFORMATION: Transposon 
<4 OOs SEQUENCE: 4 
tgcgaagagc ctgttaacg 
<21 Os SEQ ID NO 5 
&211s LENGTH: 23 
212s. TYPE: PRT 
<213> ORGANISM: Mycobacterium paratuberculosis 
10 
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Some of the examples and descriptions above include some 
conclusions about the way the invention may function, the 
inventors do not intend to be bound by those conclusions and 
functions, but put them forth only as possible explanations. 
It is to be further understood that the specific embodiments 
of the present invention as set forth are not intended as being 
exhaustive or limiting of the invention, and that many alter 
natives, modifications, and variations will be apparent to 
those of ordinary skill in the are in light of the foregoing 
examples and detailed description. Accordingly, this inven 
tion is intended to embrace all such alternatives modifica 
tions, and variations that fall within the spirit and scope of the 
following claims. 
19 
19 
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- Continued 
<4 OOs, SEQUENCE: 5 
Arg Arg Thr Gly Pro Val Gly Ile Ser Ala Val Ala Ala Lieu. His Gly 
1. 5 1O 
Trp Ser Asp Ser Gly Glin Pro 
2O 
SEQ ID NO 6 
LENGTH: 23 
TYPE PRT 
ORGANISM: Mycobacterium leprae 
<4 OOs, SEQUENCE: 6 
15 
Glin Arg Thr Ala Pro Phe Gly Val Pro Ala Ala Asp Ala Lieu. Arg Gly 
1. 5 1O 
Trp Lieu. Asp Asp Gly Arg Pro 
2O 
What is claimed and desired to be secured by Letters Patent 
is a follows: 
1. A method for isolating a bacteria comprising: 
introducing at least one mutation into the genome of a 
virulent bacteria; 
culturing the mutated bacteria in the presence of an anti 
microbial agent that kills growing but not non-growing 
bacteria; 
Selecting Surviving bacteria; 
testing the selected surviving bacteria for virulence; and 
Selecting attenuated mutant bacteria. 
2. The method of claim 1, wherein said bacteria is a myco 
bacteria. 
3. The method of claim 1, wherein said antimicrobial agent 
is a fluoroquinolone. 
4. The method of claim 3, wherein said fluoroquinolone is 
Bay y 31 18. 
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5. The method of claim 1, wherein said antimicrobial is 
D-cycloserine. 
6. The method of claim 1, wherein said mutation is intro 
duced by insertion of a transposon. 
7. The method of claim 1, wherein said mutation is a 
random mutation. 
8. A composition consisting of an attenuated mutant bac 
teria selected by the method of claim 1, said composition 
capable of stimulating an immune response against a disease 
caused by the virulent bacteria. 
9. The composition of claim 8, further comprising a phar 
maceutically acceptable carrier, diluent or excipient. 
10. The composition of claim 8, wherein said bacteria is a 
mycobacteria. 
